(NASDAQ: VKTX) reported completion of enrollment in its phase 3 VANQUISH-2 trial evaluating VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity treatment
Those who remained on therapy for a full year lost about 12%, falling short of clinical trial averages of 15 to 20%
If you are considering stopping, talk with your doctor so that any insulin or tablets can be adjusted safely
Aim for blood pressure targets your doctor recommends, often below 130/80 Treat sleep apnea if diagnosed, as it affects blood flow to the optic nerve Maintain healthy cholesterol levels to reduce overall vascular risk Avoid smoking, which significantly worsens diabetic retinopathy Treatment Options for GLP-1-Related Eye Complications If you develop mild worsening of diabetic retinopathy during early GLP-1 treatment, we may recommend observation with more frequent monitoring rather than immediate intervention
Conclusion In sum, perturbation of Met metabolism may promote the damage process of hepatobiliary injury triggered by viral infections/toxins and/or niche abnormalities, with dysregulated inflammatory and immune responses of the liver, and contribute to the obliteration and eventual fibrosis and atresia of the bile ducts in the initiation/progression of BA